Biased ligands for better cardiovascular drugs: Dissecting g-protein-coupled receptor pharmacology

Circulation Research

Volumn 109, Issue 2, 2011, Pages 205-216

  Dewire, Scott M ^a   Violin, Jonathan D ^a  

^a TREVENA INC   (United States)

Author keywords

arrestin; biased ligand; functional selectivity; G protein coupled receptor

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRENOLOL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; CARDIOVASCULAR AGENT; CARVEDILOL; CYTOSOLIC PHOSPHOLIPASE A2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; G PROTEIN COUPLED RECEPTOR KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MK 0354; NICOTINIC ACID; NICOTINIC RECEPTOR; SMALL INTERFERING RNA; TRV 120027; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ASTHMA; CARDIOVASCULAR DISEASE; CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG DEVELOPMENT; DRUG TARGETING; DYSLIPIDEMIA; ENZYME ACTIVATION; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; NONHUMAN; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; VALIDATION STUDY;

CARDIOVASCULAR AGENTS; DRUG DISCOVERY; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC;

EID: 79960382104     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.231308     Document Type: Review

References (139)

1. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev. 2010;62:265-304.
2. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller JR, Wright AC, Bergmann JE, Gaitanaris GA. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci USA. 2003;100:4903-4908. (Pubitemid 36457826)
3. Freissmuth M, Casey PJ, Gilman AG. G proteins control diverse pathways of transmembrane signaling. FASEB J. 1989;3:2125-2131.
4. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308:512-517.
5. Reiter E, Lefkowitz RJ. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab. 2006;17: 159-165.
6. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, Lefkowitz RJ. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science. 2000;290:1574-1577.
7. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA. 2001;98:2449-2454. (Pubitemid 32209502)
8. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122:261-273. (Pubitemid 41032989)
9. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem. 2000;275:17201-17210. (Pubitemid 30398969)
10. Gurevich VV, Gurevich EV. The new face of active receptor bound arrestin attracts new partners. Structure. 2003;11:1037-1042. (Pubitemid 37103064)
11. Nobles KN, Guan Z, Xiao K, Oas TG, Lefkowitz RJ. The active conformation of beta-arrestin1: Direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins1 and-2. J Biol Chem. 2007;282:21370-21381. (Pubitemid 47099966)
12. Xiao K, Shenoy SK, Nobles K, Lefkowitz RJ. Activation-dependent conformational changes in {beta}-arrestin 2. J Biol Chem. 2004;279: 55744-55753.
13. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz RJ. Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci USA. 2008;105:9988-9993.
14. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol. 2007;69:483-510.
15. Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother. 1956;11:379-393.
16. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci. 1983;220:141-162. (Pubitemid 14217337)
17. Eason MG, Jacinto MT, Liggett SB. Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs. Mol Pharmacol. 1994;45:696-702.
18. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature. 1993;365:170-175. (Pubitemid 23282064)
19. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, Miller LJ. Antagonist-stimulated internalization of the G protein-coupled cho-lecystokinin receptor. Mol Pharmacol. 1997;51:357-362. (Pubitemid 27118469)
20. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci. 2007;28:416-422.
21. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16: 488-501.
22. Ingram SL, Traynor JR. Role of protein kinase C in functional selectivity for desensitization at the mu-opioid receptor: from pharmacological curiosity to therapeutic potential. Br J Pharmacol. 2009;158: 154-156.
23. Piñeyro G. Membrane signalling complexes: implications for development of functionally selective ligands modulating heptahelical receptor signalling. Cell Signal. 2009;21:179-185.
24. Russo A, Soh UJ, Trejo J. Proteases display biased agonism at protease-activated receptors: Location matters! Mol Interv. 2009;9:87-96.
25. Galandrin S, Oligny-Longpré G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci. 2007; 28:423-430. (Pubitemid 47087968)
26. Hargreaves RJ, McKnight AT, Scholey K, Newberry NR, Street LJ, Hutson PH, Semark JE, Harley EA, Patel S, Freedman SB. L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors. Br J Pharmacol. 1992;107:494-501.
27. Jansson CC, Kukkonen JP, Näsman J, Huifang G, Wurster S, Virtanen R, Savola JM, Cockcroft V, Akerman KE. Protean agonism at alpha2A-adrenoceptors. Mol Pharmacol. 1998;53:963-968.
28. Chidiac P, Nouet S, Bouvier M. Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. Mol Pharmacol. 1996;50:662-669. (Pubitemid 26303600)
29. Niemegeers CJ, Lenaerts FM, Janssen PA. Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 1: In vivo oral pharmacology and acute toxicity. Comparison with morphine, codeine, diphenoxylate and difenoxine. Arzneimittelforschung. 1974;24:1633-1636.
30. Sorkin EM, Heel RC. Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985;29:34-56. (Pubitemid 15192974)
31. Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean R, Schteingart C, Junien JL, Trojnar J, Rivière PJ. Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors. Eur J Pharmacol. 2008;583:62-72.
32. Vaidehi N, Kenakin T. The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol. 2010;10:775-781.
33. Galandrin S, Oligny-Longpré G, Bonin H, Ogawa K, Galés C, Bouvier M. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol Pharmacol. 2008;74:162-172. (Pubitemid 351872167)
34. Rosenkilde MM, Benned-Jensen T, Frimurer TM, Schwartz TW. The minor binding pocket: A major player in 7TM receptor activation. Trends Pharmacol Sci. 2010;31:567-574.
35. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, Kobilka B. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem. 2005;280:22165-22171. (Pubitemid 40827872)
36. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, Luttrell LM, Lefkowitz RJ. Distinct beta-arrestin-and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem. 2006;281:10856-10864. (Pubitemid 43855508)
37. Maillet EL, Pellegrini N, Valant C, Bucher B, Hibert M, Bourguignon JJ, Galzi JL. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J. 2007;21:2124-2134. (Pubitemid 47026448)
38. Hoffmann C, Ziegler N, Reiner S, Krasel C, Lohse MJ. Agonist-selective, receptor-specific interaction of human P2Y receptors with beta-arrestin-1 and-2. J Biol Chem. 2008;283:30933-30941.
39. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci USA. 2009;106:9649-9654.
40. Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS. Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem. 2004;279:23214-23222. (Pubitemid 38685628)
41. Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, Kostenis E. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005;68:393-402. (Pubitemid 41058303)
42. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCR: A novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 2009;8:41-54.
43. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov. 2002;1:198-210. (Pubitemid 37361423)
44. Milligan G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol. 2009;158:5-14.
45. Casadó V, Cortés A, Mallol J, Pérez-Capote K, Ferré S, Lluis C, Franco R, Canela EI. GPCR homomers and heteromers: a better choice as targets for drug development than GPCr monomers? Pharmacol Ther. 2009;124:248-257.
46. Lohse MJ. Dimerization in GPCR mobility and signaling. Curr Opin Pharmacol. 2010;10:53-58.
47. Noor N, Patel CB, Rockman HA. Beta-arrestin: A signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol. 2010 Nov 11 [Epub ahead of print].
48. Skeggs LT, Dorer FE, Kahn JR, Lentz KE, Levine M. The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med. 1976;60:737-748.
49. Fitzsimons JT. Angiotensin, thirst, and sodium appetite: retrospect and prospect. Fed Proc. 1978;37:2669-2675. (Pubitemid 9071468)
50. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2: 247-257.
51. Begeot M, Langlois D, Vilgrain I, Saez JM. Angiotensin II (A-II) steroidogenic refractoriness in Y-1 cells in the presence of A-II receptors negatively coupled to adenylate cyclase. Endocr Res. 1987;13:301-316. (Pubitemid 17163067)
52. Sasamura H, Mifune M, Nakaya H, Amemiya T, Hiraki T, Nishimoto I, Saruta T. Analysis of Galpha protein recognition profiles of angiotensin II receptors using chimeric Galpha proteins. Mol Cell Endocrinol. 2000; 170:113-121. (Pubitemid 32012584)
53. Oppermann M, Diversé-Pierluissi M, Drazner MH, Dyer SL, Freedman NJ, Peppel KC, Lefkowitz RJ. Monoclonal antibodies reveal receptor specificity among G-protein-coupled receptor kinases. Proc Natl Acad Sci USA. 1996;93:7649-7654.
54. Olivares-Reyes JA, Smith RD, Hunyady L, Shah BH, Catt KJ. Agonist-induced signaling, desensitization, and internalization of a phosphory-lation-deficient AT1A angiotensin receptor. J Biol Chem. 2001;276: 37761-37768.
55. Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, Wei H, Lefkowitz RJ. Functional antagonism of different g protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci USA. 2005;102:1442-1447. (Pubitemid 40209189)
56. Violin JD, Dewire SM, Barnes WG, Lefkowitz RJ. G protein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angio-tensin II type 1A receptor elucidated by diacylglycerol dynamics. J Biol Chem. 2006;281:36411-36419. (Pubitemid 46041375)
57. Zhang J, Ferguson SS, Barak LS, Ménard L, Caron MG. Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization. J Biol Chem. 1996;271:18302-18305. (Pubitemid 26322677)
58. DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol. 2000;148:1267-1281.
59. DeWire SM, Kim J, Whalen EJ, Ahn S, Chen M, Lefkowitz RJ. Beta-arrestin-mediated signaling regulates protein synthesis. J Biol Chem. 2008;283:10611-10620.
60. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ. {beta}-arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphor-ylation. J Biol Chem. 2009;284:8855-8865.
61. Barnes WG, Reiter E, Violin JD, Ren XR, Milligan G, Lefkowitz RJ. Beta-arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem. 2005;280: 8041-8050. (Pubitemid 40349702)
62. Saito Y, Berk BC. Transactivation: A novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol. 2001; 33:3-7. (Pubitemid 32127779)
63. Marrero MB, Paxton WG, Schieffer B, Ling BN, Bernstein KE. Angio-tensin II signalling events mediated by tyrosine phosphorylation. Cell Signal. 1996;8:21-26. (Pubitemid 26059712)
64. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE. Direct stimulation of Jak/STAT pathway by the an-giotensin II AT1 receptor. Nature. 1995;375:247-250.
65. Inoue Y, Nakamura N, Inagami T. A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertens. 1997;15:703-714. (Pubitemid 27249985)
66. Oliveira L, Costa-Neto CM, Nakaie CR, Schreier S, Shimuta SI, Paiva AC. The angiotensin II at1 receptor structure-activity correlations in the light of rhodopsin structure. Physiol Rev. 2007;87:565-592. (Pubitemid 47086283)
67. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin ii activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA. 2003;100:10782-10787. (Pubitemid 37140105)
68. Gáborik Z, Jagadeesh G, Zhang M, Spät A, Catt KJ, Hunyady L. The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling. Endocrinology. 2003;144: 2220-2228. (Pubitemid 36629870)
69. Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, Roden DM, Wagner T, Yatani A, Vatner DE, Vatner SF, Sadoshima J. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest. 2005;115: 3045-3056. (Pubitemid 41567570)
70. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem. 2004;279:35518-35525. (Pubitemid 39100552)
71. Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther. 2011;336:296-302.
72. Wang P, Gao H, Ni Y, Wang B, Wu Y, Ji L, Qin L, Ma L, Pei G. Beta-arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem. 2003;278:6363-6370. (Pubitemid 36800895)
73. Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, Villén J, Haas W, Kovacs JJ, Shukla AK, Hara MR, Hernandez M, Lachmann A, Zhao S, Lin Y, Cheng Y, Mizuno K, Ma'ayan A, Gygi SP, Lefkowitz RJ. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci USA. 2010;107:15299-15304.
74. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, Yates JR III, Lefkowitz RJ. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA. 2007;104:12011-12016. (Pubitemid 47185621)
75. Lee MH, El-Shewy HM, Luttrell DK, Luttrell LM. Role of beta-arrestin-mediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription. J Biol Chem. 2008;283: 2088-2097.
76. Christensen GL, Kelstrup CD, Lyngsø C, Sarwar U, Bøgebo R, Sheikh SP, Gammeltoft S, Olsen JV, Hansen JL. Quantitative phosphopro-teomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics. 2010;9:1540-1553.
77. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. Beta-arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal. 2010;3:ra46.
78. Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ, Thomas WG. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phos-phorylation of type 1A angiotensin receptors. Mol Pharmacol. 2002;61: 768-777. (Pubitemid 34273156)
79. Hunton DL, Barnes WG, Kim J, Ren XR, Violin JD, Reiter E, Milligan G, Patel DD, Lefkowitz RJ. Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol. 2005;67:1229-1236. (Pubitemid 40410423)
80. Sun Y, Cheng Z, Ma L, Pei G. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem. 2002;277:49212-49219. (Pubitemid 36014350)
81. Kim J, Zhang L, Peppel K, Wu JH, Zidar DA, Brian L, DeWire SM, Exum ST, Lefkowitz RJ, Freedman NJ. Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res. 2008;103:70-79.
82. Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, Coffman TM, Rockman HA, Lefkowitz RJ. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA. 2006;103: 16284-16289. (Pubitemid 44715188)
83. Aplin M, Christensen GL, Schneider M, Heydorn A, Gammeltoft S, Kjølbye AL, Sheikh SP, Hansen JL. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and-independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin Pharmacol Toxicol. 2007;100: 289-295. (Pubitemid 46633483)
84. Aplin M, Christensen GL, Schneider M, Heydorn A, Gammeltoft S, Kjølbye AL, Sheikh SP, Hansen JL. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin Pharmacol Toxicol. 2007;100:296-301. (Pubitemid 46633484)
85. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53:557-573.
86. Violin JD, Dewire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW. Selectively engaging {beta}-arrestins at the AT1R reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther. 2010;335:572-579.
87. Chan DP, Sandok EK, Aarhus LL, Heublein DM, Burnett JC Jr. Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog. Am J Hypertens. 1992;5:354-360.
88. Cody RJ, Binkley PF, Haas GJ, Brown DM. Acute myocardial and vascular responses to specific angiotensin II antagonism in the spontaneously hypertensive rat. Am J Hypertens. 1995;8:500-508.
89. Boerrigter G, Whalen EJ, Lark M, Burnett JC. Cardiorenal actions of TRV120027, a novel, -arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: A novel therapeutic strategy for acute heart failure J Cardiac Fail. 2010;16:S73.
90. Costa-Neto CM, Miyakawa AA, Oliveira L, Hjorth SA, Schwartz TW, Paiva AC. Mutational analysis of the interaction of the N-and C-terminal ends of angiotensin II with the rat AT(1A) receptor. Br J Pharmacol. 2000;130:1263-1268. (Pubitemid 30488588)
91. Perlman S, Costa-Neto CM, Miyakawa AA, Schambye HT, Hjorth SA, Paiva AC, Rivero RA, Greenlee WJ, Schwartz TW. Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: Susceptibility to receptor mutations. Mol Pharmacol. 1997;51:301-311. (Pubitemid 27074152)
92. Reis RI, Santos EL, Pesquero JB, Oliveira L, Schanstra JP, Bascands JL, Pecher C, Paiva AC, Costa-Neto CM. Participation of transmembrane proline 82 in angiotensin II AT1 receptor signal transduction. Regul Pept. 2007;140:32-36. (Pubitemid 46275056)
93. Frishman WH. Beta-adrenergic blockers: a 50-year historical perspective. Am J Ther. 2008;15:565-576.
94. Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DP Jr, Barsh GS, Bernstein D, Kobilka BK. Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci USA. 1996;93:7375-7380. (Pubitemid 26243558)
95. Pourageaud F, Leblais V, Bellance N, Marthan R, Muller B. Role of beta2-adrenoceptors (beta-AR), but not beta1-, beta3-AR and endothe-lial nitric oxide, in beta-AR-mediated relaxation of rat intrapulmonary artery. Naunyn Schmiedebergs Arch Pharmacol. 2005;372:14-23. (Pubitemid 41414041)
96. Ruffolo RR Jr. Medicinal chemistry of adrenoceptor agonists. Drug Des Discov. 1993;9:351-367. (Pubitemid 23194510)
97. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, Rockman HA. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest. 2007;117:2445-2458.
98. Tilley DG, Rockman HA. Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther. 2006;4:417-432. (Pubitemid 43803144)
99. Patel PA, Tilley DG, Rockman HA. Beta-arrestin-mediated signaling in the heart. Circ J. 2008;72:1725-1729.
100. Yoo B, Lemaire A, Mangmool S, Wolf MJ, Curcio A, Mao L, Rockman HA. Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol. 2009;297: H1377-H1386.
101. Mangmool S, Shukla AK, Rockman HA. Beta-arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation. J Cell Biol. 2010;189:573-587.
102. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, Rockman HA. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA. 2008;105:14555-14560.
103. Kopecky SL. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol. 2006;98:1115-1119. (Pubitemid 44486154)
104. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European trial (COMET): Randomised controlled trial. Lancet. 2003;362:7-13. (Pubitemid 36835815)
105. Ruffolo RR, Jr., Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38(Suppl 2): S82-S88. (Pubitemid 20183988)
106. Feuerstein G, Yue TL, Ma X, Ruffolo RR. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis. 1998;41:17-24. (Pubitemid 28381711)
107. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, Lefkowitz RJ. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA. 2007;104:16657-16662. (Pubitemid 350211072)
108. Reiner S, Ambrosio M, Hoffmann C, Lohse MJ. Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem. 2010;285:36188-36198.
109. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ. Beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem. 2008;283:5669-5676.
110. LaRosa JC. Understanding risk in hypercholesterolemia. Clin Cardiol. 2003;26:I3-I6.
111. Gordon DJ, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316. (Pubitemid 19267219)
112. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258:94-114. (Pubitemid 41025967)
113. Sanford M, Curran MP. Niacin extended-release/simvastatin. Drugs. 2008;68:2373-2386.
114. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998;82:29U-34U; discussion 39U-41U. (Pubitemid 29047613)
115. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol. 2008;48:79-106. (Pubitemid 351738150)
116. Watts GF, Chan DC. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism. Arterioscler Thromb Vasc Biol. 2008;28:1892-1895.
117. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in Hepg2 cells. J Lipid Res. 2004;45:1835-1845. (Pubitemid 40990875)
118. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9:352-355. (Pubitemid 36362793)
119. Benyó Z, Gille A, Kero J, Csiky M, Suchánková MC, Nüsing RM, Moers A, Pfeffer K, Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005;115: 3634-3640. (Pubitemid 43121852)
120. van der Hoorn JW, de Haan W, Berbée JF, Havekes LM, Jukema JW, Rensen PC, Princen HM. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol. 2008;28: 2016-2022.
121. Li X, Millar JS, Brownell N, Briand F, Rader DJ. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. Biochem Pharmacol. 2010;80:1450-1457.
122. Morgan JM, Capuzzi DM, Guyton JR, Centor RM, Goldberg R, Robbins DC, DiPette D, Jenkins S, Marcovina S. Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther. 1996;1: 195-202.
123. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipid-emia. Am J Cardiol. 2008;101:625-630.
124. Boatman PD, Richman JG, Semple G. Nicotinic acid receptor agonists. J Med Chem. 2008;51:7653-7662.
125. Lai E, Waters MG, Tata JR, Radziszewski W, Perevozskaya I, Zheng W, Wenning L, Connolly DT, Semple G, Johnson-Levonas AO, Wagner JA, Mitchel Y, Paolini JF. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol. 2008;2:375-383.
126. Semple G, Skinner PJ, Gharbaoui T, Shin YJ, Jung JK, Cherrier MC, Webb PJ, Tamura SY, Boatman PD, Sage CR, Schrader TO, Chen R, Colletti SL, Tata JR, Waters MG, Cheng K, Taggart AK, Cai TQ, Carballo-Jane E, Behan DP, Connolly DT, Richman JG. 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A partial agonist of the nicotinic acid receptor, g-protein coupled receptor 109a with antilipolytic but no vasodilatory activity in mice. J Med Chem. 2008;51:5101-5108.
127. Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, Guerra NC, Cham L, Maciejewski-Lenoir D, Behan DP, Boatman D, Chen R, Skinner P, Ornelas P, Waters MG, Wright SD, Semple G, Connolly DT. Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem. 2007;282:18028-18036. (Pubitemid 47100250)
128. Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muehlbauer MJ, Whalen EJ, Lefkowitz RJ. Beta-arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest. 2009;119:1312-1321.
129. Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther. 2009;121:285-293.
130. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther. 2001;89:123-137. (Pubitemid 32333036)
131. Wang Q, Zhao J, Brady AE, Feng J, Allen PB, Lefkowitz RJ, Greengard P, Limbird LE. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science. 2004;304:1940-1944. (Pubitemid 38822181)
132. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687-698.
133. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of beta-arrestin-and g protein-biased agonists. Trends Mol Med. 2011;17: 126-139.
134. Kenakin TP. Pharmacological onomastics: what's in a name? Br J Pharmacol. 2008;153:432-438. (Pubitemid 351199005)
135. Griffin MT, Figueroa KW, Liller S, Ehlert FJ. Estimation of agonist activity at G protein-coupled receptors: Analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. J Pharmacol Exp Ther. 2007;321:1193-1207. (Pubitemid 46762694)
136. Kenakin T. Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity. Br J Pharmacol. 2010;160: 1045-1047.
137. Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, Christopoulos A, Summers RJ. Quantification of functional selectivity at the human {alpha}1a-adrenoceptor. Mol Pharmacol. 2011;79:298-307.
138. Bruchas MR, Chavkin C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl). 2010;210: 137-147.
139. Lee HK, Choi EB, Pak CS. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem. 2009;9:482-503.